NewGenIvf director granted 73,647 stock options

NewGenIvf Group Ltd director receives a new equity award.

Rhea-AI Filing Summary

NewGenIvf Group Ltd director receives a new equity award. Director Fong Hei Yue Tina was granted employee share options covering 73,647 Class B ordinary shares at an exercise price of $0.0001 per share.

The options were granted under the 2024 Share Incentive Plan and vest over 36 months, with 10% vesting on August 8, 2026 and the remaining options vesting in roughly 2.6% monthly tranches. Following this grant, the filing shows 73,647 options held directly.

Insider Trade Summary

Grant/Award: 73,647 shares

Grant/Award 1 txn

Insider Fong Hei Yue Tina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Share Options	73,647	$0.00	$0.00

Holdings After Transaction: Employee Share Options — 73,647 contracts (Direct)

Footnotes (2)

1. F1. The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement, dated July 8, 2026, between the Issuer and the Reporting Person (the "Option Agreement").
2. F2. The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting on August 8, 2026. Thereafter, the Employee Share Options vest monthly in tranches of approximately 2.6%.

Key Figures

Options granted: 73,647 options Exercise price: $0.0001 per share Post-transaction holdings: 73,647 options +4 more

7 metrics

Options granted 73,647 options Employee Share Options underlying Class B ordinary shares

Exercise price $0.0001 per share Conversion or exercise price for granted options

Post-transaction holdings 73,647 options Total options held directly after the grant

Initial vesting tranche 10% Vests on August 8, 2026

Ongoing vesting rate Approximately 2.6% monthly Monthly vesting after first tranche over 36 months

Vesting period 36 months Total vesting schedule for the options

Option expiration July 8, 2033 Expiration date of employee share options

Key Terms

Employee Share Options, 2024 Share Incentive Plan, vest monthly, Class B ordinary shares, +1 more

5 terms

Employee Share Options financial

"The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan"

2024 Share Incentive Plan financial

"were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement"

vest monthly financial

"The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting"

Class B ordinary shares financial

"underlying_security_title": "Class B ordinary shares""

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

exercise price financial

"conversion_or_exercise_price": "0.0001""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NewGenIvf Group Ltd (NIVF) report?

NewGenIvf reported that director Fong Hei Yue Tina received an award of employee share options. The grant covers 73,647 Class B ordinary shares as underlying stock and is recorded as a compensation-related acquisition rather than an open-market purchase.

How many NewGenIvf (NIVF) options were granted to the director?

The director was granted employee share options over 73,647 Class B ordinary shares. These options represent a new equity incentive position, with the same 73,647 options shown as held directly after the transaction in the Form 4 filing.

What is the exercise price of the NewGenIvf (NIVF) employee share options?

The employee share options have an exercise price of $0.0001 per share. This very low strike price means the director can acquire the underlying Class B ordinary shares for a nominal amount once the options vest and are exercisable.

How do the NewGenIvf (NIVF) options vest for the director?

The options vest over 36 months. According to the filing, 10% of the employee share options vest on August 8, 2026, and the remaining balance vests monthly in tranches of approximately 2.6% until fully vested over the three-year schedule.

Under which plan were the NewGenIvf (NIVF) options granted?

The employee share options were granted under NewGenIvf Group Ltd’s 2024 Share Incentive Plan. The grant is documented in an employee share option agreement dated July 8, 2026, between the company and director Fong Hei Yue Tina.

When do the NewGenIvf (NIVF) employee share options expire?

The employee share options expire on July 8, 2033. This expiration date provides a multi-year window after vesting during which the director can choose to exercise the options at the $0.0001 per share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 03:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fong Hei Yue Tina

(Last) (First) (Middle)

C/O 1/F, PIER 2, CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
NewGenIvf Group Ltd [ NIVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Share Options	$0.0001	07/08/2026		A		73,647(1)		08/08/2026(2)	07/08/2033	Class B ordinary shares	73,647	$0(1)	73,647	D

Explanation of Responses:

1. The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement, dated July 8, 2026, between the Issuer and the Reporting Person (the "Option Agreement").

2. The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting on August 8, 2026. Thereafter, the Employee Share Options vest monthly in tranches of approximately 2.6%.

	/s/ Hei Yue Tina Fong	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)